Clinical Trials
6
Active:0
Completed:4
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)Relative Bioavailability Study of HNC364 Injectable Suspension
Phase 1
Not yet recruiting
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Drug: HNC364 Injectable SuspensionDrug: Rasagiline Tablets
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06798519
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
Phase 1
Completed
- Conditions
- IPF
- Interventions
- Drug: HNC1058 Capsules
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05803850
- Locations
- 🇺🇸
Syneos Health, Miami, Florida, United States
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05523570
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: HNC042 for InjectionDrug: Placebo Comparator
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04603989
- Locations
- 🇨🇳
Jiang Yuting, Guangzhou, Guangdong, China
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: HNC664 capsules Single doseDrug: HNC664 placebos Single doseDrug: HNC664 capsules FED
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04504448
- Locations
- 🇺🇸
Pharmaron, Baltimore, Maryland, United States
- Prev
- 1
- 2
- Next
News
No news found